<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00490178</url>
  </required_header>
  <id_info>
    <org_study_id>C LF23-0121 06 02</org_study_id>
    <secondary_id>2006-002848-28</secondary_id>
    <nct_id>NCT00490178</nct_id>
  </id_info>
  <brief_title>Acceptability Study of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Type 2 Diabetes and Dyslipidemia</brief_title>
  <official_title>An Open Label, Multicenter Trial Assessing the Acceptability of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Patients With Type 2 Diabetes and Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Solvay Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Solvay Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims to assess the acceptability of a 4 week treatment of a new fixed-dose
      combination of fenofibrate and metformin, in patients with type 2 diabetes and dyslipidemia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">29</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Dyslipidemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate 80 mg and metformin 1000 mg (fixed combination)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients aged from 20 to 80 years (at inclusion visit).

          2. Type 2 diabetes treated with a stable dose of metformin for a minimum of 3 months
             either alone or in combination with another oral hypoglycaemic agent.

          3. Dyslipidemia treated with 160 mg fenofibrate (or bioequivalent formulations) for a
             minimum of 3 months either alone or in combination with a statin.

          4. And having signed a written informed consent.-

        Exclusion Criteria:

          1. Known Type 1 Diabetes, uncontrolled type 2 diabetes [HbA1c &gt; 9.5 %, Fasting plasma
             glucose (FPG) &gt; 240 mg/dL (&gt; 13.4 mmol/L) on the last performed blood sample (within
             the last 3 months)].

          2. TG &gt; 500 mg/dL (&gt; 5.65 mmol/L) on the last performed blood sample (within the last 3
             months).

          3. Women who are not surgically sterilized (i.e. bilateral tubal ligation, bilateral or
             two unilateral oophorectomies, hysterectomy) or not using adequate contraceptive
             methods (i.e. oral contraceptives, approved hormonal implant, intrauterine device,
             diaphragm with spermicide, condom with spermicide) or not postmenopausal (&gt; 1 year
             since their last menstrual period).

          4. Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Director Solvay</last_name>
    <role>Study Director</role>
    <affiliation>Solvay Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 3</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 2</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2007</study_first_submitted>
  <study_first_submitted_qc>June 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2007</study_first_posted>
  <last_update_submitted>August 31, 2007</last_update_submitted>
  <last_update_submitted_qc>August 31, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2007</last_update_posted>
  <keyword>Type II diabetes</keyword>
  <keyword>dyslipidemia</keyword>
  <keyword>metformin</keyword>
  <keyword>fenofibrate</keyword>
  <keyword>synordia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

